BioCentury
ARTICLE | Clinical News

ImmunoGen reports Phase Ib/II data for mirvetuximab soravtansine plus Keytruda in ovarian cancer

March 30, 2018 5:30 PM UTC

ImmunoGen Inc. (NASDAQ:IMGN) reported data from 14 evaluable heavily pretreated folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer patients in the dose-escalation portion of the Phase Ib/II FORWARD II trial showing that mirvetuximab soravtansine (IMGN853) plus anti-PD-1 mAb Keytruda pembrolizumab led to an overall response rate (ORR) of 43%, including six confirmed partial responses, and a median progression-free survival (PFS) of 5.2 months. In a subgroup of eight patients with "medium or high" FOLR1 expression levels, mirvetuximab soravtansine plus Keytruda led to an ORR of 63% and a median PFS of 8.6 months. Data were presented at the Society of Gynecologic Oncology meeting in New Orleans.

Based on the data, ImmunoGen said it is enrolling an additional 35 patients with "medium or high" FOLR1 expression levels in an expansion cohort of the trial...

BCIQ Company Profiles

ImmunoGen Inc.